{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:40:49Z","timestamp":1789184449205,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40272-026-00741-w","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:58:13Z","timestamp":1771253893000},"page":"217-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Guselkumab: Pediatric First Approval"],"prefix":"10.1007","volume":"28","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"741_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020530","author":"MA Boutet","year":"2018","unstructured":"Boutet MA, Nerviani A, Gallo Afflitto G, et al. Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530.","journal-title":"Int J Mol Sci"},{"key":"741_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett G, McInnes IB, Neurath MD. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385:628\u201339.","journal-title":"N Engl J Med"},{"issue":"6","key":"741_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40257-018-0406-1","volume":"19","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT, Scott LJ. Guselkumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2018;19(6):907\u201318.","journal-title":"Am J Clin Dermatol"},{"key":"741_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.clim.2018.09.001","volume":"197","author":"S Dragasevic","year":"2018","unstructured":"Dragasevic S, Stankovic B, Sokic-Milutinovic A, et al. Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: gene expression profiling study. Clin Immunol. 2018;197:86\u201395.","journal-title":"Clin Immunol"},{"key":"741_CR5","unstructured":"Johnson & Johnson. TREMFYA\u00ae (guselkumab): US prescribing information. 2025. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf. Accessed 11 Nov 2025."},{"key":"741_CR6","unstructured":"Janssen-Cilag International NV. Tremfya: EU summary of product characteristics 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tremfya. Accessed 8 Jan 2026."},{"key":"741_CR7","unstructured":"Janssen Biotech, Inc. Janssen announces U.S. FDA approval of TREMFYA\u2122 (guselkumab) for the treatment of moderate to severe plaque psoriasis [media release]. 13 July 2017. https:\/\/www.jnj.com\/media-center\/press-releases\/janssen-announces-us-fda-approval-of-tremfya-guselkumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis."},{"key":"741_CR8","unstructured":"Janssen-Cilag International NV. European Commission approves TREMFYA\u00ae (guselkumab) for the treatment of moderate to severe plaque psoriasis in the European Union [media release]. 23 Nov 2017. http:\/\/www.prnewswire.com\/news-releases\/european-commission-approves-tremfya-guselkumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-the-european-union-300561383.html."},{"key":"741_CR9","unstructured":"Janssen Pharmaceutical Companies of Johnson & Johnson. TREMFYA\u00ae (guselkumab) approved by U.S. Food and Drug Administration as the first selective interleukin (IL)-23 inhibitor for active psoriatic arthritis [media release]. 14 July 2020. https:\/\/www.prnewswire.com\/news-releases\/tremfya-guselkumab-approved-by-us-food-and-drug-administration-as-the-first-selective-interleukin-il-23-inhibitor-for-active-psoriatic-arthritis-301093009.html."},{"key":"741_CR10","unstructured":"Janssen Pharmaceutical Companies of Johnson & Johnson. European Commission approves Janssen\u2019s TREMFYA\u00ae\u25bc (guselkumab), a first-in-class treatment for active psoriatic arthritis (PsA) [media release]. 25 Nov 2020. https:\/\/www.investor.jnj.com\/investor-news\/news-details\/2020\/European-Commission-Approves-Janssens-TREMFYA-guselkumab-a-First-in-Class-Treatment-for-Active-Psoriatic-Arthritis-PsA-11-25-2020\/default.aspx."},{"key":"741_CR11","unstructured":"Johnson & Johnson. TREMFYA\u00ae (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson\u2019s leadership in inflammatory bowel disease [media release]. 11 Sep 2024. https:\/\/www.jnj.com\/media-center\/press-releases\/tremfya-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-johnson-johnsons-leadership-in-inflammatory-bowel-disease."},{"key":"741_CR12","unstructured":"Johnson & Johnson. U.S. FDA approves TREMFYA\u00ae (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn\u2019s disease [media release]. 20 Mar 2025. https:\/\/www.jnj.com\/media-center\/press-releases\/u-s-fda-approves-tremfya-guselkumab-the-first-and-only-il-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderately-to-severely-active-crohns-disease."},{"key":"741_CR13","unstructured":"Johnson & Johnson. TREMFYA\u00ae (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson\u2019s leadership in inflammatory bowel disease [media release]. 25 Apr 2025. https:\/\/www.jnj.com\/innovativemedicine\/emea\/newsroom\/tremfya-guselkumab-receives-european-commission-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-johnson-johnsons-leadership-in-inflammatory-bowel-disease."},{"key":"741_CR14","unstructured":"Johnson & Johnson. European Commission approves TREMFYA\u00ae (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn\u2019s disease [media release]. 7 May 2025. https:\/\/innovativemedicine.jnj.com\/emea\/newsroom\/european-commission-approves-tremfya-guselkumab-the-first-dual-acting-il-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderately-to-severely-active-crohns-disease."},{"key":"741_CR15","unstructured":"Johnson & Johnson. U.S. FDA approves TREMFYA\u00ae (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor [media release]. 29 Sep 2025. https:\/\/www.jnj.com\/media-center\/press-releases\/u-s-fda-approves-tremfya-guselkumab-for-the-treatment-of-pediatric-plaque-psoriasis-and-active-psoriatic-arthritis-marking-a-first-and-only-approval-for-an-il-23-inhibitor."},{"key":"741_CR16","unstructured":"Johnson & Johnson. European Commission approves TREMFYA\u00ae (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor [media release]. 19 Dec 2025. https:\/\/www.jnj.com\/innovativemedicine\/emea\/media-center\/press-releases\/european-commission-approves-tremfya-guselkumab-for-the-treatment-of-children-with-plaque-psoriasis-marking-the-first-paediatric-indication-for-an-il-23-inhibitor."},{"issue":"3","key":"741_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"741_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"key":"741_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-025-00725-2","author":"H Crauwels","year":"2025","unstructured":"Crauwels H, Ringold S, Howard S, et al. Extrapolating guselkumab efficacy to juvenile psoriatic arthritis from adult psoriatic arthritis and adult and pediatric psoriasis data. Pediatr Drugs. 2025. https:\/\/doi.org\/10.1007\/s40272-025-00725-2.","journal-title":"Pediatr Drugs"},{"issue":"10","key":"741_CR20","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/art.42534","volume":"75","author":"LE Schanberg","year":"2023","unstructured":"Schanberg LE, Mulugeta LY, Akinlade B, et al. Therapeutic development in polyarticular course juvenile idiopathic arthritis: extrapolation, dose selection, and clinical trial design. Arthritis Rheumatol. 2023;75(10):1856\u201366.","journal-title":"Arthritis Rheumatol"},{"key":"741_CR21","unstructured":"US FDA. E11A pediatric extrapolation: guidance document. 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e11a-pediatric-extrapolation. Accessed 12 Dec 2024."},{"issue":"10230","key":"741_CR22","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"10230","key":"741_CR23","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"issue":"4","key":"741_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/bjd\/ljae502","volume":"192","author":"VH Prajapati","year":"2025","unstructured":"Prajapati VH, Seyger MMB, Wilsmann-Theis D, et al. Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study. Br J Dermatol. 2025;192(4):618\u201328.","journal-title":"Br J Dermatol"},{"key":"741_CR25","unstructured":"Johnson & Johnson. Johnson & Johnson development pipeline. 2025. https:\/\/www.investor.jnj.com\/pipeline\/development-pipeline\/. Accessed 2 Dec 2025."},{"issue":"8","key":"741_CR26","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1016\/j.jid.2025.06.437","volume":"145","author":"V Sinha","year":"2025","unstructured":"Sinha V, Crauwels H, Obianom O, et al. Guselkumab pharmacokinetics and immunogenicity in pediatric psoriasis: phase 3 PROTOSTAR study [abstract no. 0432]. J Invest Dermatol. 2025;145(8):S74.","journal-title":"J Invest Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00741-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00741-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00741-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:36:33Z","timestamp":1782740193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00741-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00741-w","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license. The funding note is also updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}